PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for brain cancer: immune-boosting drug combo tested
Disease control Recruiting nowThis early-phase study tests whether adding pembrolizumab (an immunotherapy) to standard chemotherapy is safe and effective for people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. About 15 adults will receive the drug combination. The main go…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:40 UTC
-
Promising combo tackles Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of two drugs (zanubrutinib and pemetrexed) followed by zanubrutinib alone for people with a type of brain lymphoma that has returned or not responded to prior treatment. The goal is to see how well the treatment shrinks tumors and controls the disea…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New drug duo targets Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is to find the best do…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New drug combo targets brain lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests the safety of a new drug called glofitamab, given after a pre-treatment with obinutuzumab, for people with central nervous system (CNS) lymphoma. The drugs work by helping the immune system attack cancer cells. The study involves 20 participants and a…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
Promising new cocktail for brain cancer patients
Disease control Recruiting nowThis study is for people newly diagnosed with primary central nervous system lymphoma (PCNSL), a rare brain cancer. It tests a combination of four drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) to see if it works better than standard treatments. About 110 adults w…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
New drug cocktail shows promise for Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC